Lymphoma, B-Cell D016393

Description

A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.   MeSH

Subtype Terms (6)

Burkitt Lymphoma
160 drugs (93 approved, 67 experimental)

Lymphoma, AIDS-Related
41 drugs (30 approved, 11 experimental)

Lymphoma, B-Cell, Marginal Zone
209 drugs (107 approved, 102 experimental)

Lymphoma, Large B-Cell, Diffuse
394 drugs (161 approved, 233 experimental)

Lymphoma, Primary Effusion
12 drugs (10 approved, 2 experimental)

Lymphomatoid Granulomatosis
82 drugs (54 approved, 28 experimental)


Phase 2 Indicated Drugs (112)

Phase 1 Indicated Drugs (101)


Organization Involved with Phase 3 Indications (102)

Organization Involved with Phase 2 Indications (327)

Academic and Community Cancer Research United

Aegera Therapeutics

AIDS Malignancy Consortium

Alliance Foundation Trials

Allogene Therapeutics

Alopexx

Altor Bioscience

American Cancer Society, Inc.

Apogee Biotechnology Corporation

Asana BioSciences

Assistance Publique - Hôpitaux de Paris

Astellas

Autolus Limited

Azienda Ospedaliera San Giovanni Battista

BeiGene

Beijing Biohealthcare Biotechnology Co.,Ltd

Beijing InnoCare Pharma Tech Co., Ltd.

BioInvent International AB

Biothera

Bloodwise

Bristol-Myers Squibb

British Columbia Cancer Agency

Brown University

Canadian Cancer Trials Group

Cancer Research UK

Cantonal Hospital of St. Gallen

CARsgen Therapeutics, Ltd.

Case Western Reserve University

Cedars-Sinai Medical Center

Celldex Therapeutics

Celleron Therapeutics Ltd.

Centaurus Biopharma Co., Ltd.

Centre Henri Becquerel

Centre Hospitalier ABBEVILLE

Centre Hospitalier COMPIEGNE

Centre Leon Berard

Centro di Riferimento Oncologico - Aviano

Cephalon

Chang Gung University

Changhua Christian Hospital

China Medical University

Chonbuk National University

Chongqing Medical University

Chongqing Precision Biotech Co., Ltd

Chonnam National University

CHU Henri Mondor

Chulalongkorn University

Chung-Ang University

Chungnam National University

Clinica Universidad de Navarra

Consortium for Improving Survival of Lymphoma

CureTech Ltd

Curis

CytomX Therapeutics

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dong-A University

Duke University

Duran i Reynals Hospital

Dynamic Science S.L.

Dynavax Technologies Corporation

Eastern Cooperative Oncology Group

ECOG-ACRIN Cancer Research Group

Eisai

Eli Lilly

Emergent BioSolutions

Emory University

Enzon

Epizyme, Inc.

Erasmus University Rotterdam

Forty Seven, Inc.

Foshan First People's Hospital

Free University of Amsterdam

French Innovative Leukemia Organisation

Gachon University

Gateway for Cancer Research

Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany

Genor BioPharma Co., Ltd.

Genta

Genzyme

George Washington University

Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

Government of China

Government of Singapore

Government of Taiwan

Gracell Biotechnology Ltd.

Groupe Hospitalier Public Sud Oise

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Gruppo Italiano Malattie EMatologiche dell'Adulto

Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

GWT-TUD GmbH

Gyeongsang University

Hallym University

Harvard University

Hebrew University

Henan Medical University

Hoosier Cancer Research Network

Hospital Avicenne

Hospital Center of Périgueux

Hospital Center Saint-Quentin

Hospital Clinico Lozano Blesa

Hospital Universitario Central de Asturias

Hospital Universitari Son Dureta

HOVON - Dutch Haemato-Oncology Association

Huizhou People's Central Hospital

Humanigen

Humboldt University

Icahn School of Medicine at Mount Sinai

Idera

ImmunogenX

Immunomedics

ImmunoVaccine Technologies, Inc.

Incyte

Indiana University

Inje University

Innovative Cellular Therapeutics Co., Ltd.

Institut Bergonié

Instytut Hematologii i Transfuzjologii, 02-776 Warszawa ul. Indiry Gandhi 14

International Extranodal Lymphoma Study Group

Italian Lymphoma Foundation

Jaen Hospital

Jerez Hospital

Jichi Medical University

Jilin University

Jinan University

Jinlin University

Johannes Gutenburg University

Johns Hopkins University

Juno Therapeutics, Inc.

J. W. Goethe University

Kantonsspital Graubünden

Kaohsiung Medical University

Kartos Therapeutics, Inc.

Kepler University

Kite Pharma, Inc.

Korea Cancer Center Hospital

Korea University

Kosin University

Kyowa Hakko Kirin

Kyungpook University

La Jolla Pharmaceutical Company

León Hospital

LifeBridge Health

Ligand Pharmaceuticals

Louisiana State University

Loxo Oncology

Loyola University

Ludwig Maximilians University

Lund University

Mackay Medical College

Mahidol University

Mansoura University

Marche Polytechnic University

McGill University

Medical City Children's Hospital, Dallas

Medical College of Wisconsin

Medical University of Vienna

MedImmune

Medivation

Memorial Sloan-Kettering Cancer Center

Merck

Merck KGaA

MethylGene Inc.

Miltenyi Biotec, Inc.

Molecular Templates

Morales i Meseguer Hospital

Mundipharma

National Cancer Institute, France

National Cheng Kung University

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute on Aging (NIA)

National Institutes of Health (NIH)

National Marrow Donor Program

National Taiwan University

Neumedicines Inc.

New York Medical College

North Central Cancer Treatment Group

Northwestern University

Ohio State University

Oncology Specialists, S.C.

Oregon Health and Science University

Ortho Biotech, Inc.

Osaka University

Ospedale S. Giovanni Bellinzona

Pardee Foundation

Pavlov First Saint Petersburg State Medical University

People's Liberation Army of China

Pharmatech

Philogen S.p.A.

Plexxikon

Polish Lymphoma Research Group

Portola Pharmaceuticals

Precision BioSciences, Inc.

Pusan National University

Quebec Clinical Research Organization in Cancer

RedHill Biopharma

Regeneron

Rhode Island Hospital

Rigel Pharmaceuticals

Royal Marsden Hospital NHS Trust

Rush University

Rutgers University

Sanofi

Sanofi-Synthelabo

Schering-Plough

SCRI Development Innovations

Segovia Hospital

Seoul National University

Sevion Therapeutics

Shanghai Longyao Biotechnology Inc., Ltd.

Shanghai YingLi Pharmaceutical Co. Ltd.

Shantou University

Shenzhen Geno-Immune Medical Institute

Shenzhen University

Singapore General Hospital

Sinocelltech Ltd.

Siriraj Hospital

Son Llatzer Hospital

Southampton University Hospital NHS Foundation Trust

Southwest Oncology Group

Sponsor GmbH

Stanford University

State University of New York, Buffalo

Stony Brook University

Sunesis Pharmaceuticals

Sungkyunkwan University

Swedish Orphan Biovitrum

Swiss Group for Clinical Cancer Research

Szpital Morski im. PCK

Taichung Veterans General Hospital

Takara Bio Inc.

TCR2 Therapeutics

Technical University of Munich

Tel Aviv University

Telik

Temple University

Territorial Hospital Group (GHT) Rance Emeraude

TG Therapeutics, Inc.

The Alfred Hospital

The Alvin and Lois Lapidus Cancer Institute

The Beijing Pregene Science and Technology Company, Ltd.

The Christie NHS Foundation Trust

The EMMES Corporation

The Leukemia and Lymphoma Society

Thermo Fisher Scientific

Thomas Jefferson University

Timmune Biotech Inc.

Transgene

Translational Research Institute for Metabolism and Diabetes, Florida

Triumvira Immunologics, Inc.

Universidad Autonoma de Madrid

Universidad Autonoma de Nuevo Leon

Universidad Complutense de Madrid

University Hospital Plymouth NHS Trust

University of Arizona

University of Birmingham

University of Bologna

University of Bordeaux

University of Caen-Normandie

University of Cagliari

University of California, Los Angeles

University of California, San Francisco

University of Cantabria

University of Chicago

University of Cologne

University of Colorado, Denver

University of Duisburg-Essen

University of Erlangen-Nuremberg

University of Florida

University of Freiburg

University of Hamburg

University of Heidelberg

University of Illinois at Chicago

University of Las Palmas de Gran Canaria

University of Leeds

University of London

University of Lyon

University of Manchester

University of Mannheim

University of Massachusetts

University of Medicine and Dentistry of New Jersey

University of Miami

University of Michigan

University of Milan

University of Minnesota

University of Nantes

University of Nebraska

University of Nice Sophia Antipolis

University of North Carolina at Chapel Hill

University of Nottingham

University of Oxford

University of Paris

University of Pavia

University of Pennsylvania

University of Picardie Jules Verne

University of Rennes

University of Rochester

University of Roma La Sapienza

University of Salamanca

University of Southern California

University of South Florida

University of Texas at Houston

University of Texas, San Antonio

University of Toronto

University of Tuebingen

University of Turin

University of Ulm

University of Washington

University of Western Brittany

University of Wisconsin

University of Witten/Herdecke

Vanderbilt University

VentiRx Pharmaceuticals Inc.

Verastem, Inc.

Virgen de la Concha Hospital

Vita-Salute University of Milano. Italy

Wake Forest University

Washington University in St. Louis

Wayne State University

Wonju Christian Hospital

Wyeth

Xuzhou Medical University

Xynomic Pharmaceuticals, Inc.

Yale University

Yonsei University

Zhejiang DTRM Biopharma

Zhejiang Hisun Pharmaceutical Co. Ltd.

Zhejiang University

Organization Involved with Phase 1 Indications (104)

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.